[Clinical trials of restenosis after PTCA and QOL of patients after PTCA].
Okamoto
S
S
First Department of Internal Medicine, School of Medicine, Mie University.
Nakano
T
T
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D017225:Atherectomy, Coronary; D002986:Clinical Trials as Topic; D023903:Coronary Restenosis / Q000517:prevention & control*; D015118:Eicosapentaenoic Acid; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011788:Quality of Life; D015607:Stents; D014192:Trapidil / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D005231:Fatty Acids, Unsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D015118:Eicosapentaenoic Acid; D014192:Trapidil